89180-50-7

Usage

Uses

Used in Organic Synthesis:
5,6-dichloropyridazin-4-amine is utilized as a key intermediate in organic synthesis for the creation of a variety of biologically active molecules. Its structural features allow for the development of new compounds with specific therapeutic or functional properties.
Used in Pharmaceutical Industry:
In the pharmaceutical sector, 5,6-dichloropyridazin-4-amine serves as a building block for the synthesis of pharmaceuticals. Its ability to be modified and incorporated into complex molecular structures makes it valuable for the development of new drugs with potential therapeutic benefits.

Upstream product

• 14161-11-6 3,4,5-trichloropyridazine 
• 105398-92-3 3,4-dichloro-5-(N,N-dimethylaminomethyleneamino)pyridazine 
• 7664-41-7 ammonia 
• 6339-19-1 5-amino-4-chloropyridazin-3(2H)-one 

Downstream Products

• 111163-92-9 7-chloro-2-phenyl-oxazolo[4,5-d]pyridazine 
• 20744-39-2 4-aminopyridazine 
• 61071-29-2 5-amino-4-chloro-3-hydrazinopyridazine 

Relevant academic research and scientific papers

Transformations of N-Heteroarylformamidines and N-Heteroarylformamidine Oximes. New Syntheses and Transformations of Oxazolopyridazines

New syntheses of oxazolopyridazine derivatives 7 and 11 were achieved by the cyclization of substituted N-pyridazin-5-ylformamide oximes 6 and 10.Under mild reaction conditions the transformations of the substituted amino group at position 2 of the oxazolopyridazine system 7 occured to produce the compounds 11, 14, and 15, while under more drastic reaction conditions the nucleophilic attack at carbon at position 2 followed by the ring opening of the oxazole part of the molecule was observed to give the compounds 13, 16, 17 and 18. - Keywords: Cyclization with C-O bond formation; Substituted N-pyridazin-5-ylformamidines and -formamide oximes; Oxazolopyridazines; Ring opening of oxazolopyridazines

SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE

The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.

Substituted heteroaryl compounds and compositions and uses thereof (by machine translation)

The invention discloses substituted heteroaryl compounds and compositions thereof and their use. The compounds of formula (I) compound or type shown in (I) a compound represented by stereo isomers, tautomers, nitrogen oxide, solvate, metabolite, pharmaceutically acceptable salt or its prodrug. The invention also provides a pharmaceutical composition, the compounds and pharmaceutical compositions can be regulated protein kinase, particularly Aurora kinase and JAK kinase activity, for the prevention, treatment, treatment and reduce protein kinase, in particular JAK kinase activity mediated diseases or disorders. (by machine translation)

NOVEL COMPOUNDS

The present invention discloses novel compounds inhibiting LRRK2 kinase activity, the preparation processes thereof, the compositions containing them, as well as the use in treating diseases characterized by LRRK2 kinase activity, particularly Parkinson's disease and Alzheimer's disease.

Synthesis and anticonvulsant activity of 3H-imidazo[4,5-c]-pyridazine, 1H-imidazo[4,5-d]pyridazine and 1H-benzimidazole analogues of 9-(2-fluorobenzyl)-6-methylamino-9H-purine

The 3H-imidazo[4,5-c]pyridazine, 1H-imidazo[4,5-d]pyridazine, and 1H-benzimidazole analogues of the potent anticonvulsant purine 9-(2-fluorobenzyl)-6-methylamino-9H-purine (1, 78U79) were synthesized and tested for anticonvulsant activity. The 3H-imidazo[4,5-c]pyridazines 8 and 9 were prepared in five stages from 3,4,5-trichloropyridazine (2). The 1H-imidazolo[4,5-d]pyridazine 15 was synthesized in four stages from 5-[(benzyloxy)methyl]-1,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one (10a). The benzimidazole analogues 18 and 20 were prepared from 2,6-dinitroaniline in three stages. These compounds were one-tenth or less as active as 1 in protecting rats against maximal electroshock-induced seizures.

Pyridazinylurea plant regulators

Pyridazinylurea plant regulators of the formula STR1 and acid addition salts thereof; wherein R is alkyl or cycloalkyl, R1 is hydrogen or alkyl, each X independently is halogen, alkoxy, alkylthi or alkylsulfonyl, and p is 0, 1 or 2.